S Chae1, K M Kang1, H J Kim1, E Kang1, S Y Park2, J H Kim3, S H Kim3, S W Kim4, E K Kim1. 1. Department of Surgery. 2. Department of Pathology, and. 3. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam; and. 4. Department of Surgery, Daerim St. Mary's Hospital, Seoul, Republic of Korea.
Abstract
Background: The neutrophil-lymphocyte ratio (nlr) has been reported to correlate with patient outcome in several cancers, including breast cancer. We evaluated whether the nlr can be a predictive factor for pathologic complete response (pcr) after neoadjuvant chemotherapy (nac) in patients with triple-negative breast cancer (tnbc). Methods: We analyzed the correlation between response to nac and various factors, including the nlr, in 87 patients with tnbc who underwent nac. In addition, we analyzed the association between the nlr and recurrence-free survival (rfs) in patients with tnbc. Results: Of the 87 patients, 25 (28.7%) achieved a pcr. A high Ki-67 index and a low nlr were significantly associated with pcr. The pcr rate was higher in patients having a high Ki-67 index (≥15%) than in those having a low Ki-67 index (35.7% vs. 0%, p = 0.002) and higher in patients having a low nlr (≤1.7) than in those having a high nlr (42.1% vs. 18.4%, p = 0.018). In multiple logistic analysis, a low nlr remained the only predictive factor for pcr (odds ratio: 4.274; p = 0.008). In the survival analysis, the rfs was significantly higher in the low nlr group than in the high nlr group (5-year rfs rate: 83.7% vs. 66.9%; log-rank p = 0.016). Conclusions: Our findings that the nlr is a predictor of pcr to nac and also a prognosticator of recurrence suggest an association between response to chemotherapy and inflammation in patients with tnbc. The pretreatment nlr can be a useful predictive and prognostic marker in patients with tnbc scheduled for nac.
Background: The neutrophil-lymphocyte ratio (nlr) has been reported to correlate with patient outcome in several cancers, including breast cancer. We evaluated whether the nlr can be a predictive factor for pathologic complete response (pcr) after neoadjuvant chemotherapy (nac) in patients with triple-negative breast cancer (tnbc). Methods: We analyzed the correlation between response to nac and various factors, including the nlr, in 87 patients with tnbc who underwent nac. In addition, we analyzed the association between the nlr and recurrence-free survival (rfs) in patients with tnbc. Results: Of the 87 patients, 25 (28.7%) achieved a pcr. A high Ki-67 index and a low nlr were significantly associated with pcr. The pcr rate was higher in patients having a high Ki-67 index (≥15%) than in those having a low Ki-67 index (35.7% vs. 0%, p = 0.002) and higher in patients having a low nlr (≤1.7) than in those having a high nlr (42.1% vs. 18.4%, p = 0.018). In multiple logistic analysis, a low nlr remained the only predictive factor for pcr (odds ratio: 4.274; p = 0.008). In the survival analysis, the rfs was significantly higher in the low nlr group than in the high nlr group (5-year rfs rate: 83.7% vs. 66.9%; log-rank p = 0.016). Conclusions: Our findings that the nlr is a predictor of pcr to nac and also a prognosticator of recurrence suggest an association between response to chemotherapy and inflammation in patients with tnbc. The pretreatment nlr can be a useful predictive and prognostic marker in patients with tnbc scheduled for nac.
Authors: Carla S Fisher; Cynthia X Ma; William E Gillanders; Rebecca L Aft; Timothy J Eberlein; Feng Gao; Julie A Margenthaler Journal: Ann Surg Oncol Date: 2011-07-02 Impact factor: 5.344
Authors: Christoph Suppan; Vesna Bjelic-Radisic; Marlen La Garde; Andrea Groselj-Strele; Katharina Eberhard; Hellmut Samonigg; Hans Loibner; Nadia Dandachi; Marija Balic Journal: BMC Cancer Date: 2015-12-29 Impact factor: 4.430
Authors: Angelo Restivo; Ivana Maria Francesca Cocco; Giuseppe Casula; Francesco Scintu; Francesco Cabras; Mario Scartozzi; Luigi Zorcolo Journal: Br J Cancer Date: 2015-09-15 Impact factor: 7.640
Authors: Aleix Prat; Cheng Fan; Aranzazu Fernández; Katherine A Hoadley; Rossella Martinello; Maria Vidal; Margarita Viladot; Estela Pineda; Ana Arance; Montserrat Muñoz; Laia Paré; Maggie C U Cheang; Barbara Adamo; Charles M Perou Journal: BMC Med Date: 2015-12-18 Impact factor: 8.775
Authors: Mei-Yin C Polley; Roberto A Leon-Ferre; Samuel Leung; Angela Cheng; Dongxia Gao; Jason Sinnwell; Heshan Liu; David W Hillman; Abraham Eyman-Casey; Judith A Gilbert; Vivian Negron; Judy C Boughey; Minetta C Liu; James N Ingle; Krishna Kalari; Fergus Couch; Jodi M Carter; Daniel W Visscher; Torsten O Nielsen; Matthew P Goetz Journal: Breast Cancer Res Treat Date: 2021-01-03 Impact factor: 4.872
Authors: Ling Bo Xue; Yong Hong Liu; Bo Zhang; Yan Fang Yang; Dong Yang; Li Wei Zhang; Jian Jin; Jie Li Journal: Medicine (Baltimore) Date: 2019-01 Impact factor: 1.889